2015/12/14

Inthera Bioscience raises EUR 3.4 million in seed financing round

Inthera Bioscience, a Swiss biopharmaceutical company focused on the development of first-in-class targeted small molecule therapies for solid tumors, today announced the closing of a EUR 3.4m financing round led by MS Ventures, with equal contribution from Aglaia Oncology Fund II and Novo Seeds. EVA Basel also participated in the financing.

Press Release

back to overview